Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

ngs derived from Anadys' completed strategic restructuring.

Operating expenses were $9.7 million for the third quarter of 2008, compared to $10.0 million for the third quarter of 2007. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $0.7 million and $1.4 million for the third quarter of 2008 and 2007, respectively.

The net loss was $9.3 million for the third quarter of 2008, compared to net income of $12.3 million for the third quarter of 2007. Basic and diluted net loss per common share was $0.32 in the third quarter of 2008, compared to net income per common share of $0.43 in the third quarter of 2007. Non-cash share-based expense resulted in a $0.03 increase in basic and diluted net loss per share for the third quarter of 2008 compared to a $0.05 decrease in basic and diluted net income per share for the third quarter 2007.

During the nine months ended September 30, 2008 the Company had no revenue, compared to $23.9 million for the same period in 2007. The revenue recognized in the first nine months of 2007 was primarily derived from the amortization of an upfront payment and a milestone payment under a prior collaboration and the recognition of the previously deferred revenue upon termination of the collaboration. Operating expenses during the nine months ended September 30, 2008 were $25.2 million compared to $28.1 million for the nine months ended September 30, 2007. The decrease in operating expenses was a result of cost savings derived from Anadys' completed restructuring partially offset by increases in development costs for ANA598 and ANA773. For the nine months ended September 30, 2008, Anadys reported a net loss of $23.9 million, compared to $1.4 million for the same period last year. Basic and diluted net loss per common share was $0.83 for the nine months ended September 30, 2008, compared to $0.05 for the same period in 2007.

Recent Development Program Highlights

-- Phase
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015 ... novel biological drugs to treat cancer, viral infections ... Professor Sir John Bell , the Regius ... of the Office for the Strategic Coordination of ... immediate effect.      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ...
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 /PRNewswire/ ... two studies in which Caris Molecular Intelligence®, the ... molecular similarities and differences between several rare and ... treatment strategies that have the potential to improve ... Poster Session B at the Society of Gynecologic ...
(Date:3/27/2015)... Earlier this year, the Capillus272Pro™ received ... in adult men and women with androgenic alopecia (AGA) ... of IIa-V and Fitzpatrick Classification of Skin phototypes I-IV. ... over-promise and under-deliver, FDA Clearance underscores the safety and ... more than 80 million men and women who suffer ...
(Date:3/27/2015)... , March 27, 2015   SurePure, ... liquid photopurification, announced today that the Company has ... the continued trading of SurePure ("SURP") securities on ... marketplace for entrepreneurial and development stage companies. ... introduced standards and eligibility requirements designed to improve ...
Breaking Biology Technology:Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2
... Glycominds Ltd., a,bio-diagnostics company specializing in glycan biomarkers ... cancer, announced today,entering into a research agreement with ... center to develop a new diagnostics blood test ... work with FCCC on this project," stated Dr. ...
... BEDMINSTER, N.J., Oct. 25 NPS,Pharmaceuticals, Inc. (Nasdaq: ... hydrochloride by the Japanese Pharmaceuticals and Medical,Devices Agency ... NPS will receive a milestone payment plus royalties ... Holdings, which will market the,drug in Japan. Kirin ...
... World-Renowned RNase and RNA Researchers, SOMERSET, N.J., ... ribonuclease (RNase) therapeutics will be the focus of,scientific ... Alfacell,Corporation (Nasdaq: ACEL ). Moderated by ... and David Sidransky, M.D., Alfacell,s scientific,advisory board chairman, ...
Cached Biology Technology:Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests 2NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 3Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 4
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report ... markets for Hand Geometry in US$ Thousands. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... fuel emissions, planting new forests, or managing existing forests ... ability to act as a carbon sink. Research published ... Management shows that although planting trees alone is unlikely ... a significant effect in the longer term. Rik ...
... Rochelle, NY, April 7, 2008 The American Medical ... of women in medicine and the improvement of women,s ... ) as its official journal. Journal of Womens Health ... Inc ( http://www.liebertpub.com ). We are proud to ...
... documentary An Inconvenient Truth is a powerful example of ... audience. What is up for debate is whether it ... caused by human activities. Climate change experts express their ... in articles just published online in Springers journal, GeoJournal. ...
Cached Biology News:Forests' long-term potential for carbon offsetting 2Scientists debate the accuracy of Al Gore's documentary 'An Inconvenient Truth' 2
... tool provides the firm pressure necessary ... in tubes or plates. The multifunctional ... that firmly holds thin-wall 0.5 ml ... opening or closing. A side slot ...
... Gene Pulser Xcell microbial system, 100 ... used for electroporation of bacterial and ... main unit, PC module for exponential ... sterile cuvettes (5 each of 0.1 ...
... Clear yellow solution. In ... thimerosal, and other proprietary ... Diluent formulated to stabilize ... antibody conjugates at high ...
... Pulser Xcell eukaryotic system, 100 ... is used for electroporation of ... the main unit, CE module ... or square-wave pulses, ShockPod shocking ...
Biology Products: